Genegrafts Ltd.

Gene therapy for excitable tissue disorders, atrial fibrillation, modulating excitable tissues

Genegrafts was founded by Yair Feld, Shimon Marom, Meira Melamed Frank, Lior Yankelson and Lior Gepstein and started operations in 2003. It is based in the Technological Incubator founded by the Technion R&D Foundation Ltd. The company has raised seed funding from the Office of the Chief Scientist of the Israeli Ministry of Industry and Trade and 4 major venture capital funds. It has also received frunding from a large international, strategic partner.

Yair Feld, M.D., Ph.D., CEO, Director and Founder
Lior Gepstein, M.D., Ph.D., Prof., Founder
Shimon Marom, M.D., Ph.D., Director and Founder
Meira Melamed Frank, Ph.D., Founder
Lior Yankelson
Zoya Gluzman, PhD, Project Manager Cardiology
Tal Bresler PhD, Project Manager Neurology

Inder Verma, Ph.D.
Steve A. N. Goldstein, M.D., Ph.D.
Daniel Dagan, Prof., PhD
Jeffrey Olgin, M.D.
Daniel Dagan Ph.D., Prof.

Building 30, MATAM - Advanced Technology Center
P.O.Box 15054
Haifa 31905
Israel
Phone: +972-4-8546-618
Fax: +972-4-8501-246

The company has developed a novel technology platform, based on the transplantation of cell grafts, extracted from the patient own body. This cell grafts are genetically modified to over-express specific ion channels. The electrical properties of the target organ can be modulated in a predetermined way. The technology will be used for the treatment of cardiac arrhythmias, neurological disorders and diabetes mellitus type II.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.